MedTrace Logo

Prospective Validation of the OHI Index

NCT05882175 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-05-13

No results posted yet for this study

Summary

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

Conditions

  • HLH
  • Hemophagocytic Lymphohistiocytoses
  • Hemophagocytic Syndrome
  • Hematologic Malignancy
  • Hematologic Neoplasms

Sponsors & Collaborators

  • Children's Hospital Medical Center, Cincinnati

    collaborator OTHER

  • Rabin Medical Center

    collaborator OTHER

  • Sheba Medical Center

    collaborator OTHER_GOV

  • Schneider Children's Medical Center, Israel

    collaborator OTHER

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Adi Zoref-Lorenz · Meir Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2030-03-03
Completion
2030-03-03

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05882175 on ClinicalTrials.gov